BIO-Europe Spring® 2017: Newron CEO on Xadago and upcoming pipeline milestones

April 11, 2017

Newron CEO Stefan Weber discusses the company's Parkinson's therapy, Xadago (safinamide), on the eve of its US market approval during the recent BIO-Europe Spring partnering conference. Newron, a clinical-stage biopharma company listed on the Swiss Exchange, is focused on the development of novel therapies for patients with diseases of the central nervous system. As well as Xadago—developed in partnership with Zambon, which holds global marketing rights to the product with the exception of Asia—Newron has three other clinical assets in its pipeline. Its most advanced is sarizotan, a serotonin 1A (5-HT1A) receptor agonist in development for the treatment of orphan disease Rett syndrome.

 

Click here for more coverage of the activities held during BIO-Europe Spring

Previous Video
BIO-Europe Spring® 2017: Incorporating flexibility into your R&D strategy
BIO-Europe Spring® 2017: Incorporating flexibility into your R&D strategy

Strategic decisions made early in clinical development often have an impact on the downstream commercial po...

Next Video
BIO-Europe Spring® 2017: Seventure Partners predicts bright future for microbiome opportunities
BIO-Europe Spring® 2017: Seventure Partners predicts bright future for microbiome opportunities

Seventure Partners’ Eric de la Fortelle explains to Informa Pharma Intelligence’s Mike Ward how the venture...